Go offline with the Player FM app!
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC
Manage episode 473319706 series 3256997
In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including:
- Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapies
- Treatment sequencing and preferred treatment options in patients with brain metastases
- Results from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancer
- Thoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trial
Program faculty:
Stephanie L. Graff, MD, FACP, FASCO
Director of Breast Oncology, Brown University Health
Co-Lead, Breast Cancer Translational Disease Research Group
Legorreta Cancer Center at Brown University
Associate Professor of Medicine
Warren Alpert Medical School of Brown University
Providence, Rhode Island
Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts
Resources:
To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic.
191 episodes
Manage episode 473319706 series 3256997
In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including:
- Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapies
- Treatment sequencing and preferred treatment options in patients with brain metastases
- Results from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancer
- Thoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trial
Program faculty:
Stephanie L. Graff, MD, FACP, FASCO
Director of Breast Oncology, Brown University Health
Co-Lead, Breast Cancer Translational Disease Research Group
Legorreta Cancer Center at Brown University
Associate Professor of Medicine
Warren Alpert Medical School of Brown University
Providence, Rhode Island
Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts
Resources:
To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic.
191 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.